Apogee's APG990 Phase 1 data show a 60-day half-life and strong tolerability, supporting long-interval dosing. A 2025 trial will compare APG279 to Dupixent.
10 mid-cap stocks jumped in last week, including QuantumScape, Lantheus Holdings, Sunrun, Kymera Therapeutics, Apogee Therapeutics, Joby Aviation, Crinetics Pharmaceuticals, Dyne Therapeutics, Summit Therapeutics, Plug Power and XPeng Inc.
As of March 14, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
U.S. stocks traded lower toward the end of trading, with the Dow Jones falling around 350 points on Tuesday. The Dow traded down 0.91% to 38,633.24 while the NASDAQ fell 1.85% to 15,906.92. The S&P 500 also fell, dropping, 1.05% to 5,076.98.
Shares of SOPHiA GENETICS SA (NASDAQ: SOPH) fell sharply during Tuesday’s session after the company reported worse than expected fourth-quarter earnings and issued 2024 guidance.
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 250 points on Tuesday. The Dow traded down 0.64% to 38,741.00 while the NASDAQ fell 1.64% to 15,942.27. The S&P 500 also fell, dropping, 0.85% to 5,087.09.
Apogee Therapeutics unveils promising Phase 1 data for APG777, a lead candidate for atopic dermatitis treatment. Interim results show sustained biomarker inhibition and favorable safety profile. Phase 2 trial scheduled for 2024.
